Esophageal Cancer

Phase II trial of TNFerade initiated

Published in Gene Therapy Weekly, December 26th, 2002

GenVec, Inc., (GNVC), a biopharmaceutical company developing gene-based medicines, announced the commencement of a phase II clinical trial for its lead oncology product candidate, TNFerade, as part of first line therapy in patients with nonmetastatic esophageal cancer.

A total of approximately 55 patients at 13 sites throughout the United States will participate in the study.

In the phase II study, TNFerade will be added to the current standard of care, which is a chemotherapeutic regimen of cisplatin/5-FU and radiation therapy followed by surgery. The primary endpoint will be complete tumor response, which will be determined through surgical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-12-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry